Letrozol Accord (Letrozole)

Letrozole blocks the aromatase enzyme, which converts androgens into estrogens in peripheral tissues. By inhibiting this conversion, circulating estrogen levels fall, depriving estrogen‑dependent breast cancer cells of a key growth signal and thereby slowing disease progression.

The dosage of Letrozol Accord is determined by the prescribing clinician based on the individual patient's condition, renal and hepatic function, and treatment goals. Patients should follow the specific instructions provided by their healthcare professional.

Safety data for letrozole during pregnancy and lactation are lacking, and the product is generally contraindicated in women who are pregnant, may become pregnant, or are breastfeeding. Effective contraception is recommended for women of childbearing potential while on therapy.

To order Letrozol Accord, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Letrozol Accord (letrozole) is a third‑generation aromatase inhibitor with a long half‑life and high potency, often preferred for its once‑daily dosing. Compared with anastrozole or exemestane, letrozole may achieve slightly greater estrogen suppression, though clinical choice depends on patient tolerance, prior therapy and physician preference.

Store Letrozol Accord at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Letrozol Accord is taken orally, usually as a whole tablet swallowed with water. It is administered with or without food, according to the prescribing physician’s instructions, and should be taken at the same time each day to maintain consistent blood levels.

Serious risks include severe bone loss leading to fractures, liver enzyme elevations indicating hepatic injury, and rare thromboembolic events such as deep‑vein thrombosis. Patients should report persistent bone pain, jaundice, unexplained swelling or shortness of breath to their healthcare provider promptly.

Letrozol Accord should not be used in premenopausal women unless ovarian function is fully suppressed, in patients with known hypersensitivity to letrozole or any tablet excipients, and in women who are pregnant, planning pregnancy, or breastfeeding. Caution is also advised for individuals with severe hepatic impairment.